Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
News Menu

News

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

GlobeNewswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Follow us on Google News Follow us on Google News

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress.

Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Related Symbols

Symbol Last Chg %Chg
SGMO 0.0740 -0.1003 -57.54%
Sangamo Therapeutics Inc

Most Popular News

Double explosure with businesss charts and financial district of megapolis city by Golden Dayz via Shutterstock 1
Stock Index Futures Climb as Chipmakers Rebound and Bond Yields Fall, U.S. Economic Data in Focus
Jen-Hsun Huan NVIDIA's Founder, President and CEO by jamesonwu1972 via Shutterstock 2
Wedbush Delivers Blunt Message on Nvidia Stock Ahead of Earnings
Tesla dealership with cars in lot by Jetcityimage via iStock 3
Massive Options in Tesla Shows Investors Placing Huge Bets on TSLA Stock
Nike swoosh on building by Wu Yi via Unsplash 4
Dividend Aristocrat or Dividend Cuts: How to Evaluate the NKE Stock Payout as the Nike Turnaround Drags On
A close-up shot of JD Vance_ Image by Maxim Elramsisy via Shutterstock_ 5
Can We Really ‘Grow Our Way Out Of’ $40 Trillion in National Debt? Why One Economist Says ‘The US Has No Chance.’
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.